Regula Launches Full Support for Digital Travel Credentials in Latest Software Update
Regula, a global developer of forensic devices and identity verification solutions, has updated its Regula Document Reader SDK. Now, the software fully supports the new Digital Travel Credential (DTC) format, aligned with the International Civil Aviation Organization (ICAO) standards. This enhancement enables governments, airlines, and border control authorities worldwide to process travel documents with unmatched security, efficiency, and ease—whether on-site or remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115990355/en/

With Regula Document Reader SDK, travelers can create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document like ePassport. (Graphic: Regula)
The DTC is a secure digital solution that streamlines travel experiences. It consolidates key personal information into a single virtual document that travelers can store on their mobile devices or upload to their digital wallets and share whenever needed. The main goal of the DTC is to facilitate clearance procedures during travel and ensure that people are eligible to enter their destination before they board a flight.
The ICAO has defined three types of DTC, each offering varying levels of convenience and security for travelers.
- DTC Type 1 allows travelers to create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document, stored on their personal device. However, travelers must still carry the original document for identity verification.
- DTC Type 2, issued by authorities, combines a cryptographically linked Virtual Component (DTC-VC) and a Physical Component (DTC-PC). This format adds an extra layer of security while maintaining a connection to the physical document.
- DTC Type 3 represents the future of travel identification: a fully digital document issued directly by authorities. Unlike the other types, it eliminates the need for a physical ID, streamlining identity verification for a completely digital experience.
Now, with Regula Document Reader SDK, users can create and reprocess DTC-VC from ePassports, and verify it by passing DTC-VC data as input. Also, support for handling DTC-PC has been introduced. The updated Regula Document Reader SDK can:
- read the document’s RFID chip with a smartphone or passport reader and create DTC-VC;
- recognize, read, and verify DTC-VC with a smartphone, passport reader, or server;
- read DTC-PC with a smartphone or passport reader, parse its data, and verify it.
The updated Regula Document Reader SDK is equipped with advanced features that fully support DTC implementation.
- Trustworthy NFC verification. First and foremost, it provides trusted server-side NFC verification of the ID so it ensures accurate and trustworthy DTC-VC creation. Since all the data from the chip can be verified on a secure server, there is no need to question the reliability of the checks performed by a mobile device (which is prone to manipulation). Such an approach ensures that the virtual component of a traveler’s document is secure and taken from an authentic ID.
- Compliance with ICAO guidelines and technical reports. Regula Document Reader SDK not only verifies DTCs but also guarantees that each DTC fully complies with ICAO guidelines and technical reports. This makes Regula’s solution an indispensable tool for airlines and governments so they can be confident in the validity of travelers’ DTCs.
- Future-ready technology. In addition to supporting DTC-VC, Regula’s technology is fully compatible with handling DTC-PC. Looking further ahead, Regula is ready to process DTC Type 3, a digital passport that is expected in the next several years.
To facilitate the fast and smooth global application of DTCs, Regula Document Reader SDK relies on the most comprehensive identity document template database, which is owned and maintained by Regula. Currently, it contains more than 14,000 ID templates from 251 countries and territories, and it’s constantly growing.
Regula Document Reader SDK is designed for easy integration into third-party applications, allowing clients to incorporate this advanced DTC-ready technology seamlessly into their existing systems. With customizable options, businesses can adapt the solution to meet their unique operational requirements while providing end users with a secure, streamlined digital experience.
“We see that the world is rapidly moving to embrace digital IDs. According to the Forrester Consulting study commissioned by Regula earlier in 2024, nearly half of businesses around the world, 42%, are actively integrating digital IDs into their systems. For the Aviation sector, this rate is even higher: 50%. By ensuring full DTC support in the latest update of Regula Document Reader SDK, we are helping our clients to smoothly transition to the future of travel, where secure, digital-first solutions redefine the passenger experience,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the capabilities of the updated Regula Document Reader SDK, read the release documentation on Regula’s website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification. Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115990355/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom